SPECTRAL AI, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.69 USD | -1.17% |
|
-2.33% | -31.71% |
| 05-09 | Spectral AI, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-07 | Transcript : Spectral AI, Inc., Q1 2024 Earnings Call, May 07, 2024 |
| Sales 2024 * | 30.06M 2.39B | Sales 2025 * | 50.15M 3.99B | Capitalization | 29.89M 2.38B |
|---|---|---|---|---|---|
| Net income 2024 * | -15M -1.19B | Net income 2025 * | -25M -1.99B | EV / Sales 2024 * | 0.46 x |
| Net cash position 2024 * | 16.1M 1.28B | Net cash position 2025 * | 14.78M 1.18B | EV / Sales 2025 * | 0.3 x |
| P/E ratio 2024 * |
-1.88
x | P/E ratio 2025 * |
-1.17
x | Employees | 78 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.61% |
More Fundamentals
* Assessed data
More news
Latest transcript on Spectral AI, Inc.
More press releases
| 1 day | -1.46% | ||
| 1 week | -2.33% | ||
| Current month | -5.62% | ||
| 1 month | -15.58% | ||
| 3 months | -19.23% | ||
| 6 months | -40.21% | ||
| Current year | -31.71% |
1 week
1.61
1.83
1 month
1.612.02
Current year
1.613.72
1 year
1.6119.50
3 years
1.6119.50
5 years
1.6119.50
10 years
1.6119.50
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Carlson
CEO | Chief Executive Officer | 60 | 01-02 |
Vincent Capone
DFI | Director of Finance/CFO | 57 | 28/02/22 |
Mary Regan
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Cotton
CHM | Chairman | 63 | 10/09/23 |
| Director/Board Member | 63 | 11-26 | |
Peter Carlson
CEO | Chief Executive Officer | 60 | 01-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/05/24 | 1.68 | -1.75% | 82 801 |
| 10/05/24 | 1.71 | +1.79% | 406,211 |
| 09/05/24 | 1.68 | -2.89% | 109,530 |
| 08/05/24 | 1.73 | +0.58% | 262,292 |
| 07/05/24 | 1.72 | 0.00% | 158,105 |
Delayed Quote Nasdaq, May 13, 2024 at 04:54 pm
More quotes
Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid health care providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.
Calendar
13/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.71
USD
Average target price
5.867
USD
Spread / Average Target
+243.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.71% | 29.89M | |
| +6.03% | 32.93B | |
| +18.24% | 7.94B | |
| +30.15% | 4.19B | |
| -26.91% | 2.8B | |
| -17.66% | 1.38B | |
| -33.33% | 1.17B | |
| +9.82% | 966M | |
| -37.56% | 900M | |
| -26.60% | 839M |
- Stock Market
- Equities
- MDAI Stock
